Revised forecast
Fiscal year ending December 2026 · Full yearPrevious forecast published 13 February 2026The bar length represents the relative magnitude of change, based on the item that changed the most in this document. The percentage change shown by the dotted line is calculated from the two reported figures because the company did not provide the rate.
The healthcare business and the agri segment of the Other business have been performing above plan. While the Company aims to achieve revenue growth by strengthening advertising and promotional investment, forecasts for adjusted EBITDA, operating income and ordinary income remain unchanged from the previous forecasts in light of the seasonality of the agri segment and uncertainty in the external environment.
Business structure improvement expenses of ¥265 million were recorded in the previous interim consolidated accounting period, and a ¥0 million loss on valuation of investment securities was recorded in the current interim consolidated accounting period.
| Item | Details |
|---|---|
| Net Sales | 52,000 Millions of yen → 53,000 Millions of yen（+1.9%） |
| Operating profit | 3,200 Millions of yen → 3,200 Millions of yen |
| Ordinary income | 2,800 Millions of yen → 2,800 Millions of yen |
| Fiscal Period Covered | Fiscal year ending December 2026 |
| Period Covered | Full year |
| Publication date of previous forecast | 13 February 2026 |
| Previous-period results | Revenue: ¥50,370 million; operating income: ¥3,123 million; ordinary income: ¥2,365 million; net loss attributable to owners of the parent: ¥805 million |
| Reason for the revision | The healthcare business and the agri segment of the Other business have been performing above plan. While the Company aims to achieve revenue growth by strengthening advertising and promotional investment, forecasts for adjusted EBITDA, operating income and ordinary income remain unchanged from the previous forecasts in light of the seasonality of the agri segment and uncertainty in the external environment. |
| Details and amount of extraordinary loss | Business structure improvement expenses of ¥265 million were recorded in the previous interim consolidated accounting period, and a ¥0 million loss on valuation of investment securities was recorded in the current interim consolidated accounting period. |
| Dividend forecast revision | No change (whether the dividend forecast has been revised from the most recently announced forecast: No) |
| Consolidated / non-consolidated | Consolidated |
Items this document does not state (2)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The healthcare business and the agri segment of the Other business have been performing above plan. From the third quarter onward, the Company aims to achieve revenue growth by strengthening advertising and promotional investment. However, in light of the seasonality of the agri segment and uncertainties including the situation in the Middle East and inflation, profit forecasts remain unchanged under its policy of continuing to invest for growth.